Endpoints News 生物医药· Anna Brown·· 20 小时前AI 评分35
AbbVie 与 Disco 生物制药达成高达 2.54 亿美元合作开发实体瘤靶向药物
AbbVie and Disco strike deal worth up to $2.54B for solid tumor targets
AI 导读
AbbVie 与德国 Disco 生物制药达成合作协议,将共同开发抗体偶联药物和 T 细胞接合器,合作金额最高达 2.54 亿美元。
正文
AbbVie is partnering with preclinical cancer biotech Disco Pharmaceuticals to build out its antibody-drug conjugate and T cell engager programs.
The Cologne, Germany-based biotech will …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news